Mariathasan15 has found that TGF-β is highly expressed in tumor areas that lack CD8+ T cell infiltration, and therapeutic co-administration of TGF-β-blocking and anti-PD-L1 antibodies facilitates T cell penetration into the tumor center, and elicits vigorous anti-tumor immunity and tumor regression. This evidence concerns the gene CD274 and neoplasm.